0001193125-19-241987.txt : 20190910 0001193125-19-241987.hdr.sgml : 20190910 20190910160603 ACCESSION NUMBER: 0001193125-19-241987 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20190910 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190910 DATE AS OF CHANGE: 20190910 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MyoKardia Inc CENTRAL INDEX KEY: 0001552451 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455500552 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37609 FILM NUMBER: 191085397 BUSINESS ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-741-0900 MAIL ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d801823d8k.htm 8-K 8-K
MyoKardia Inc false 0001552451 0001552451 2019-09-10 2019-09-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2019

 

MYOKARDIA, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

  

001-37609

 

44-5500552

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

333 Allerton Ave.

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 741-0900

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common Stock

  

MYOK

  

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

Item 8.01 Other Events.

On September 10, 2019 (the “Effective Date”), MyoKardia, Inc. issued a press release titled “MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit

No.

   

Description

         
 

99.1

   

Press Release, dated September 10, 2019

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 10, 2019

 

 

MyoKardia, Inc.

             

 

 

By:

  

/s/ Cynthia Ladd

 

 

 

Cynthia Ladd

 

 

 

General Counsel

EX-99.1 2 d801823dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO    News Release

MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy

in Obstructive Hypertrophic Cardiomyopathy Patients

Planned Study Will Assess Effect of Mavacamten on the Need for SRT Among

HCM Patients Referred for Invasive Procedures

SOUTH SAN FRANCISCO, Calif., September 10, 2019 – MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The study will be conducted at leading HCM centers that regularly perform surgical myectomy or alcohol septal ablation procedures, with support from the established referral networks at those centers. The randomized, double-blind study will enroll symptomatic, obstructive HCM patients referred for SRT, and MyoKardia anticipates that enrollment will begin in the first half of 2020.

The study’s Executive Committee is being chaired by Steve Nissen, M.D., Chief Academic Officer at the Cleveland Clinic Heart and Vascular Institute. Milind Desai, M.D., Director, Clinical Operations, Cleveland Clinic Heart and Vascular Institute, is serving as Principal Investigator. The study is being run by Cleveland Clinic C5 Research

“This study is designed to address the question of whether mavacamten, which addresses the underlying cause of HCM, can be an effective alternative to surgical procedures which can only address removal of the physical obstruction of oHCM,” said Jay Edelberg, Senior Vice President of Clinical Development at MyoKardia. “This septal reduction therapy trial will allow us to focus on obstructive HCM patients who have been referred for SRT and to expand our knowledge for the broader HCM community. The data from this blinded, controlled study will supplement the clinical data from our ongoing Phase 3 EXPLORER pivotal trial in understanding the potential of mavacamten in treatment of these patients.”

HCM is a chronic, progressive condition in which the heart muscle thickens due to excess contraction. In the obstructive form of HCM, the wall of the septum thickens and may block the flow of blood from the left ventricle to the aorta. Each year, approximately 1,500 patients with obstructive HCM undergo septal reduction therapy in the United States. SRT is performed as either an open-heart surgical procedure, known as a myectomy, or injection of alcohol into the heart muscle, which causes the heart muscle cells in the thickened area to die. Both procedures are intended to reduce the thickness of the septal wall and alleviate obstruction.

“HCM can be a debilitating disease, interfering with the ability of patients to go about the activities of daily living and putting them at long-term risk of atrial fibrillation, stroke and heart failure,” said Dr. Desai.

MyoKardia is developing mavacamten for the treatment of HCM. Mavacamten was specifically developed to correct the abnormal mechanics of the HCM heart by normalizing the number of myosin-actin cross-bridges that drive the excessive contractility, left ventricular hypertrophy and reduced compliance characteristic of HCM. In the company’s Phase 2 PIONEER-HCM clinical trial of patients with obstructive HCM, mavacamten reduced or eliminated the obstruction of the left ventricular outflow tract, resulting in improvements in how patients feel (as measured by New York Heart Association classification), and how their hearts are functioning (based on peak VO2 measured by cardiopulmonary exercise testing).

“MyoKardia is committed to leadership within the broader HCM community, including the development of robust evidence regarding treatment alternatives,” commented Tassos Gianakakos, president and CEO at MyoKardia. “We look forward to results from this and other potential studies outside of our registration program to further inform referral and treatment decisions for patients across the full spectrum of this potentially debilitating disease.”

 

Driven by the Heart

333 Allerton Avenue, South San Francisco, CA 94080 / +1 650 351 4705 / myokardia.com

MyoKardia is currently conducting the pivotal Phase 3 EXPLORER-HCM clinical trial of mavacamten in patients with symptomatic (NYHA Class II or III) obstructive HCM. Enrollment in the EXPLORER study completed in August 2019 at clinical sites in the U.S., Europe, and Israel. Topline data from the EXPLORER-HCM trial are anticipated in the second quarter of 2020. The EXPLORER trial, along with data from the MAVA long-term extension study, as well as MyoKardia’s ongoing and completed clinical trials of mavacamten, are expected to form the basis for a registrational submission to the U.S. Food and Drug Administration.

About Mavacamten (MYK-461)

Mavacamten is a novel, oral, allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). Mavacamten is intended to reduce cardiac muscle contractility by inhibiting the excessive myosin-actin cross-bridge formation that underlies the excessive contractility, left ventricular hypertrophy and reduced compliance characteristic of HCM. MyoKardia is currently advancing mavacamten in a pivotal Phase 3 clinical trial, known as the EXPLORER-HCM study, in patients with symptomatic, obstructive HCM and a Phase 2 clinical trial, the MAVERICK-HCM study, in patients with symptomatic non-obstructive HCM. Two long-term follow-up studies are also ongoing: the PIONEER open-label extension study of obstructive HCM patients from MyoKardia’s Phase 2 PIONEER-HCM trial, and the MAVA-LTE, an extension study for patients who have completed either the EXPLORER-HCM or MAVERICK-HCM trials. In April 2016, the U.S. FDA granted Orphan Drug Designation for mavacamten for the treatment of symptomatic obstructive HCM.

About MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious cardiovascular diseases. MyoKardia’s initial focus is on the development of small molecule therapeutics aimed at the muscle proteins of the heart that modulate cardiac muscle contraction and underlying diseases of systolic and diastolic dysfunction. MyoKardia applies a precision medicine approach to develop its therapeutic candidates for patient populations with shared characteristics, such as causal genetic mutations or disease subtypes. MyoKardia has discovered a pipeline of product candidates directed at diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly 461) in Phase 3 and Phase 2 clinical trials for hypertrophic cardiomyopathies (HCM); MYK-491 in Phase 2 for patients with stable heart failure; and MYK-224, in Phase 1 development for HCM.

MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

Forward-Looking Statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the timing of the commencement of the SRT study and the availability of data from our Phase 3 EXPLORER-HCM study in patients with obstructive HCM as well as our expectation with respect to release of data from the EXPLORER-HCM study, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates, as well as those set forth

in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Michelle Corral

Corporate Communications & Investor Relations

MyoKardia, Inc.

650-351-4690

mcorral@myokardia.com

Hannah Deresiewicz (investors)

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Steven Cooper (media)

Edelman

415-486-3264

steven.cooper@edelman.com

EX-101.SCH 3 myok-20190910.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 myok-20190910_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 myok-20190910_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g801823g0910205237316.jpg GRAPHIC begin 644 g801823g0910205237316.jpg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ilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d801823d8k.htm d801823dex991.htm myok-20190910.xsd myok-20190910_lab.xml myok-20190910_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false ZIP 8 0001193125-19-241987-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-241987-xbrl.zip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end XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 d801823d8k_htm.xml IDEA: XBRL DOCUMENT 0001552451 2019-09-10 2019-09-10 MyoKardia Inc false 0001552451 8-K 2019-09-10 DE 001-37609 44-5500552 333 Allerton Ave. South San Francisco CA 94080 (650) 741-0900 false false false false Common Stock MYOK NASDAQ false XML 12 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Document and Entity Information
Sep. 10, 2019
Cover [Abstract]  
Entity Registrant Name MyoKardia Inc
Amendment Flag false
Entity Central Index Key 0001552451
Document Type 8-K
Document Period End Date Sep. 10, 2019
Entity Incorporation State Country Code DE
Entity File Number 001-37609
Entity Tax Identification Number 44-5500552
Entity Address, Address Line One 333 Allerton Ave.
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 741-0900
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol MYOK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d801823d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d801823d8k.htm" ] }, "labelLink": { "local": [ "myok-20190910_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "myok-20190910_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "myok-20190910.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "myok", "nsuri": "http://www.myokardia.com/20190910", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d801823d8k.htm", "contextRef": "duration_2019-09-10_to_2019-09-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d801823d8k.htm", "contextRef": "duration_2019-09-10_to_2019-09-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com//20190910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" }